BARDA developed a digital endpoint for detecting the earliest signs of the flu

The US government’s Biomedical Advanced Research and Development Authority (BARDA) has partnered with Empatica to develop a digital endpoint for detecting the earliest signs of the flu. Through the use of the Embrace2 wearable and Empatica data analysis expertise, they engaged in a prospective study monitoring healthy individuals throughout the flu season with the aim to develop an early detection system. Following the outbreak of the Covid-19 pandemic, BARDA and Empatica renewed their partnership to utilize EmbracePlus and the Care suite for Covid-19 early detection.

BARDA, alongside industry partners, promotes the development of medical countermeasures to protect American citizens in response to health security threats, via the development of necessary vaccines, drugs, therapies, and diagnostic tools. Through their integrated approach, they aim to address emergencies such as chemical, biological, radiological and nuclear incidents, pandemic influenza and infectious diseases.